Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3719250 | 0.93 | P2RX3 (0.40) | P2RX3P2RX2KDM5AKDM4CKDM5B | |
| SCHEMBL3718553 | 0.87 | P2RX3 (0.42) | P2RX3P2RX2PDE4APDE4BPDE4C | |
| SCHEMBL3776905 | 0.85 | DHODH (0.45) | KDM5AKDM4CKDM5BPDE4APDE4B | |
| SCHEMBL28416982 | 0.85 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL13019154 | 0.82 | P2RX3 (0.53) | P2RX3P2RX2 | |
| SCHEMBL3727443 | 0.81 | DHODH (0.41) | P2RX3P2RX2KDM5AKDM4CKDM5B | |
| SCHEMBL13019149 | 0.80 | — | — | |
| SCHEMBL13019148 | 0.80 | — | — | |
| SCHEMBL13019156 | 0.78 | P2RX3 (0.73) | P2RX3P2RX2 | |
| SCHEMBL20921559 | 0.77 | ALDH1A1 (0.39) | P2RX3P2RX2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234981-B1 | NOVEL IMIDAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-03-30 | — | — | EP | disclosed |
| EP-2234981-B1 | NOVEL IMIDAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-03-30 | — | — | EP | disclosed |
| US-7858654-B2 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858654-B2 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858654-B2 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2234981-A1 | NOVEL IMIDAZOLE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| WO-2009077365-A1 | NOVEL IMIDAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077365-A1 | NOVEL IMIDAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885KDM5A 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.